JP2008534472A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008534472A5 JP2008534472A5 JP2008502385A JP2008502385A JP2008534472A5 JP 2008534472 A5 JP2008534472 A5 JP 2008534472A5 JP 2008502385 A JP2008502385 A JP 2008502385A JP 2008502385 A JP2008502385 A JP 2008502385A JP 2008534472 A5 JP2008534472 A5 JP 2008534472A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- cycloalkyl
- phenyl
- pyrimidin
- dimethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 125000000217 alkyl group Chemical group 0.000 claims 17
- -1 1,2-dihydro-indenyl Chemical group 0.000 claims 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000000753 cycloalkyl group Chemical group 0.000 claims 13
- BWIHJLOBZMKPKS-UHFFFAOYSA-N 2-(1h-pyrazol-5-yl)pyrimidine Chemical class N1C=CC(C=2N=CC=CN=2)=N1 BWIHJLOBZMKPKS-UHFFFAOYSA-N 0.000 claims 12
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 11
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 9
- 125000001624 naphthyl group Chemical group 0.000 claims 9
- 125000001424 substituent group Chemical group 0.000 claims 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000003545 alkoxy group Chemical group 0.000 claims 6
- 125000001188 haloalkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 102000004257 Potassium Channel Human genes 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 4
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 4
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims 4
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 4
- 230000000694 effects Effects 0.000 claims 4
- 125000002541 furyl group Chemical group 0.000 claims 4
- 125000004438 haloalkoxy group Chemical group 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 4
- 108020001213 potassium channel Proteins 0.000 claims 4
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 4
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 4
- 125000004076 pyridyl group Chemical group 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 125000001544 thienyl group Chemical group 0.000 claims 4
- 125000003282 alkyl amino group Chemical group 0.000 claims 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010034759 Petit mal epilepsy Diseases 0.000 claims 2
- 208000028017 Psychotic disease Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 208000028311 absence seizure Diseases 0.000 claims 2
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 206010015037 epilepsy Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 239000000651 prodrug Substances 0.000 claims 2
- 229940002612 prodrug Drugs 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims 2
- NOIAFRXJAOIRIO-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-6-methyl-n-(4-methylphenyl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=CC(C)=CC=2)=N1 NOIAFRXJAOIRIO-UHFFFAOYSA-N 0.000 claims 1
- GCYURZUJNGSNKB-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-6-methyl-n-naphthalen-2-ylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=C3C=CC=CC3=CC=2)=N1 GCYURZUJNGSNKB-UHFFFAOYSA-N 0.000 claims 1
- KCZNYEKQVDFBBF-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-6-methyl-n-phenylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=CC=CC=2)=N1 KCZNYEKQVDFBBF-UHFFFAOYSA-N 0.000 claims 1
- DGBGJAANMYAVCJ-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n,n-diethyl-6-methylpyrimidin-4-amine Chemical compound CCN(CC)C1=CC(C)=NC(N2C(=CC(C)=N2)C)=N1 DGBGJAANMYAVCJ-UHFFFAOYSA-N 0.000 claims 1
- PXQJUGVKEYTNBD-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n-(4-methylphenyl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC=2C=CC(C)=CC=2)=N1 PXQJUGVKEYTNBD-UHFFFAOYSA-N 0.000 claims 1
- KTCGBPVALCAPDU-UHFFFAOYSA-N 2-(3,5-dimethylpyrazol-1-yl)-n-[3-(trifluoromethyl)phenyl]pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC=2C=C(C=CC=2)C(F)(F)F)=N1 KTCGBPVALCAPDU-UHFFFAOYSA-N 0.000 claims 1
- FCTRCVYLPZXYLH-UHFFFAOYSA-N 5-bromo-n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Br)C(NC=2C=CC(Cl)=CC=2)=N1 FCTRCVYLPZXYLH-UHFFFAOYSA-N 0.000 claims 1
- XYUUDWDCHUFTKW-UHFFFAOYSA-N 5-bromo-n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Br)C(NC2CCCCC2)=N1 XYUUDWDCHUFTKW-UHFFFAOYSA-N 0.000 claims 1
- ASQXYGAONBBSHT-UHFFFAOYSA-N 5-chloro-n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Cl)C(NC=2C=CC(Cl)=CC=2)=N1 ASQXYGAONBBSHT-UHFFFAOYSA-N 0.000 claims 1
- TZLDAYRGEQCNRS-UHFFFAOYSA-N 5-chloro-n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(Cl)C(NC2CCCCC2)=N1 TZLDAYRGEQCNRS-UHFFFAOYSA-N 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000035473 Communicable disease Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 150000001204 N-oxides Chemical class 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006399 Premature Obstetric Labor Diseases 0.000 claims 1
- 206010036600 Premature labour Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 230000003676 hair loss Effects 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- TTXQIWXVTCZSTO-UHFFFAOYSA-N n-(3,4-dichlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC=2C=C(Cl)C(Cl)=CC=2)=N1 TTXQIWXVTCZSTO-UHFFFAOYSA-N 0.000 claims 1
- HEKSTMZFTPWLRQ-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)-5-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=C(C)C(NC=2C=CC(Cl)=CC=2)=N1 HEKSTMZFTPWLRQ-UHFFFAOYSA-N 0.000 claims 1
- MYCRDMLFNQGDBT-UHFFFAOYSA-N n-(4-chlorophenyl)-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC=2C=CC(Cl)=CC=2)=N1 MYCRDMLFNQGDBT-UHFFFAOYSA-N 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- BTRUVNBLFGQQHU-UHFFFAOYSA-N n-benzyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NCC=2C=CC=CC=2)=N1 BTRUVNBLFGQQHU-UHFFFAOYSA-N 0.000 claims 1
- XITVRRQKYRJRMA-UHFFFAOYSA-N n-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)pyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC=CC(NC2CCCCC2)=N1 XITVRRQKYRJRMA-UHFFFAOYSA-N 0.000 claims 1
- SBBUCGYZZUIBIB-UHFFFAOYSA-N n-cyclopentyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine Chemical compound N1=C(C)C=C(C)N1C1=NC(C)=CC(NC2CCCC2)=N1 SBBUCGYZZUIBIB-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- WSDQIHATCCOMLH-UHFFFAOYSA-N phenyl n-(3,5-dichlorophenyl)carbamate Chemical group ClC1=CC(Cl)=CC(NC(=O)OC=2C=CC=CC=2)=C1 WSDQIHATCCOMLH-UHFFFAOYSA-N 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 208000026440 premature labor Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 claims 1
- 150000003230 pyrimidines Chemical class 0.000 claims 1
- 230000008085 renal dysfunction Effects 0.000 claims 1
- 201000009881 secretory diarrhea Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Claims (17)
異性体若しくはその異性体の混合物、そのN−オキシド、そのプロドラッグ又は薬剤として許容されるその塩
(式中、
nは0、1、2又は3であり、
XはO、S又はNR’を表し、但し、
R’は水素、アルキル、特にメチル又はエチル、シクロアルキル又はシクロアルキル−アルキルを表すか、
又は、nが0でありXがNR’である場合、R’は、Y及びそれらが結合している窒素と一緒になって複素環を形成しており、前記複素環は、アルキル及びフェニルからなる群から選択される1つ若しくは2つの置換基で任意選択で置換されており、
Yはアルキル、シクロアルキル、アルキル−シクロアルキル、アミノ−アルキル、アルキル−アミノ、アルキル−アミノ−アルキル、ヒドロキシ−アルキル、アルコキシ−アルキル、アルケニル、フェニル、ベンジル、ナフチル、1,2,3,4−テトラヒドロ−ナフチル、インデニル、1,2−ジヒドロ−インデニル、フラニル、チエニル、ピラニル、テトラヒドロ−ピラン−4−イル、ピリジニル、インドリニル又はキノリニルを表し、前記フェニル、ベンジル、ナフチル、1,2,3,4−テトラヒドロ−ナフチル、インデニル、1,2−ジヒドロ−インデニル、フラニル、チエニル、ピラニル、2,3,5,6−テトラヒドロ−4H−ピラン−4−イル、ピリジニル、インドリニル及びキノリニル基は、アルキル、アミノ−アルキル、アルキル−アミノ、アルキル−アミノ−アルキル、ヒドロキシ−アルキル、アルコキシ−アルキル、シクロアルキル、シクロアルキル−アルキル、アルケニル、ハロ、ハロアルキル、ヒドロキシ、アルコキシ、メチレンジオキシ、ハロアルコキシ、シアノ、ニトロ、アミノ、フェニル及びモルホリニルからなる群から選択される1つ若しくは複数の置換基で任意選択で置換されていてよいか、
又は、nが0でありXがNR’である場合、Yは、R’及びそれらが結合している窒素と一緒になって複素環を形成しており、前記複素環は、アルキル及びフェニルからなる群から選択される1つ若しくは2つの置換基で任意選択で置換されており、
R1、R2、R3及びR4は互いに独立に、水素、アルキル、シクロアルキル、シクロアルキル−アルキル、シクロアルキル、シクロアルキル−アルキル、ハロ、ハロアルキル、ヒドロキシ、アルコキシ、アルコキシ−カルボニル、ハロアルコキシ、シアノ、ニトロ及び/又はアミノを表す)。 A pyrazolyl-pyrimidine derivative of the formula I,
An isomer or a mixture of isomers thereof, an N-oxide thereof, a prodrug thereof or a pharmaceutically acceptable salt thereof, wherein
n is 0, 1, 2 or 3;
X represents O, S or NR ′, provided that
R ′ represents hydrogen, alkyl, in particular methyl or ethyl, cycloalkyl or cycloalkyl-alkyl,
Or when n is 0 and X is NR ′, R ′ is taken together with Y and the nitrogen to which they are attached to form a heterocyclic ring, said heterocyclic ring from alkyl and phenyl Optionally substituted with one or two substituents selected from the group consisting of:
Y is alkyl, cycloalkyl, alkyl-cycloalkyl, amino-alkyl, alkyl-amino, alkyl-amino-alkyl, hydroxy-alkyl, alkoxy-alkyl, alkenyl, phenyl, benzyl, naphthyl, 1,2,3,4- Represents tetrahydro-naphthyl, indenyl, 1,2-dihydro-indenyl, furanyl, thienyl, pyranyl, tetrahydro-pyran-4-yl, pyridinyl, indolinyl or quinolinyl, said phenyl, benzyl, naphthyl, 1,2,3,4 -Tetrahydro-naphthyl, indenyl, 1,2-dihydro-indenyl, furanyl, thienyl, pyranyl, 2,3,5,6-tetrahydro-4H-pyran-4-yl, pyridinyl, indolinyl and quinolinyl groups are alkyl, amino -Alkyl Alkyl-amino, alkyl-amino-alkyl, hydroxy-alkyl, alkoxy-alkyl, cycloalkyl, cycloalkyl-alkyl, alkenyl, halo, haloalkyl, hydroxy, alkoxy, methylenedioxy, haloalkoxy, cyano, nitro, amino, phenyl And optionally substituted with one or more substituents selected from the group consisting of morpholinyl,
Or when n is 0 and X is NR ′, Y is taken together with R ′ and the nitrogen to which they are attached to form a heterocycle, said heterocycle from alkyl and phenyl Optionally substituted with one or two substituents selected from the group consisting of:
R 1 , R 2 , R 3 and R 4 are independently of one another hydrogen, alkyl, cycloalkyl, cycloalkyl-alkyl, cycloalkyl, cycloalkyl-alkyl, halo, haloalkyl, hydroxy, alkoxy, alkoxy-carbonyl, haloalkoxy Represents cyano, nitro and / or amino).
R’は水素、アルキル、シクロアルキル又はシクロアルキル−アルキルを表すか、又は、nが0でありXがNR’である場合、R’は、Y及びそれらが結合している窒素と一緒になって複素環を形成しており、前記複素環は、アルキル及びフェニルからなる群から選択される1つ若しくは2つの置換基で任意選択で置換されている、請求項1又は2に記載のピラゾリル−ピリミジン誘導体。 X represents O, S or NR ′, provided that
R ′ represents hydrogen, alkyl, cycloalkyl or cycloalkyl-alkyl, or when n is 0 and X is NR ′, R ′ is taken together with Y and the nitrogen to which they are attached. A heterocycle is formed, wherein the heterocycle is optionally substituted with one or two substituents selected from the group consisting of alkyl and phenyl. Pyrimidine derivatives.
R’は水素、アルキル、シクロアルキル又はシクロアルキル−アルキルを表す、請求項1又は2に記載のピラゾリル−ピリミジン誘導体。 X represents O, S or NR ′, provided that
The pyrazolyl-pyrimidine derivative according to claim 1 or 2, wherein R 'represents hydrogen, alkyl, cycloalkyl or cycloalkyl-alkyl.
XがNR’であり、但し、
R’は、Y及びそれらが結合している窒素と一緒になって複素環を形成しており、前記複素環は、アルキル及びフェニルからなる群から選択される1つ若しくは2つの置換基で任意選択で置換されている、請求項1又は2に記載のピラゾリル−ピリミジン誘導体。 n is 0,
X is NR ′, provided that
R ′, together with Y and the nitrogen to which they are attached, forms a heterocycle, which is optionally substituted with one or two substituents selected from the group consisting of alkyl and phenyl 3. A pyrazolyl-pyrimidine derivative according to claim 1 or 2, optionally substituted.
XがNHであり、
Yがアルキル、シクロアルキル、アルキル−シクロアルキル、ヒドロキシ−アルキル、フェニル、ベンジル又はナフチルを表し、
R1及びR2がメチルを表し、
R3が水素、メチル、エチル又はプロピルを表し、
R4が水素、メチル、エチル、プロピル、クロロ、ブロモ、エトキシカルボニル及び/又はシアノを表す
請求項1に記載のピラゾリル−ピリミジン誘導体。 n is 0,
X is NH,
Y represents alkyl, cycloalkyl, alkyl-cycloalkyl, hydroxy-alkyl, phenyl, benzyl or naphthyl;
R 1 and R 2 represent methyl,
R 3 represents hydrogen, methyl, ethyl or propyl;
The pyrazolyl-pyrimidine derivative according to claim 1, wherein R 4 represents hydrogen, methyl, ethyl, propyl, chloro, bromo, ethoxycarbonyl and / or cyano.
XがNHであり、
Yがフェニル又はベンジルを表し、前記フェニル及びベンジル基はアルキル、ハロ、ハロアルキル及びアルコキシからなる群から選択される1つ若しくは2つの置換基で任意選択で置換されていてよく、
R1及びR2がメチルを表し、
R3が水素、メチル、エチル又はプロピルを表し、
R4が水素、メチル、エチル、プロピル、クロロ、ブロモ、エトキシカルボニル又はシアノを表す、請求項1に記載のピラゾリル−ピリミジン誘導体。 n is 0,
X is NH,
Y represents phenyl or benzyl, wherein the phenyl and benzyl groups may be optionally substituted with one or two substituents selected from the group consisting of alkyl, halo, haloalkyl and alkoxy;
R 1 and R 2 represent a methyl,
R 3 represents hydrogen, methyl, ethyl or propyl;
The pyrazolyl-pyrimidine derivative according to claim 1, wherein R 4 represents hydrogen, methyl, ethyl, propyl, chloro, bromo, ethoxycarbonyl or cyano.
シクロペンチル−[2−(3,5−ジメチル−ピラゾール−1−イル)−6−メチル−ピリミジン−4−イル]−アミン;
[2−(3,5−ジメチル−ピラゾール−1−イル)−6−メチル−ピリミジン−4−イル]−ジエチル−アミン;
[2−(3,5−ジメチル−ピラゾール−1−イル)−6−メチル−ピリミジン−4−イル]−フェニル−アミン;
[2−(3,5−ジメチル−ピラゾール−1−イル)−6−メチル−ピリミジン−4−イル]−p−トリル−アミン;
(3,4−ジクロロ−フェニル)−[2−(3,5−ジメチル−ピラゾール−1−イル)−6−メチル−ピリミジン−4−イル]−アミン;
[2−(3,5−ジメチル−ピラゾール−1−イル)−6−メチル−ピリミジン−4−イル]−ナフタレン−2−イル−アミン;
[2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−(3−トリフルオロメチル−フェニル)−アミン;
シクロヘキシル−[2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−アミン;
[5−クロロ−2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−シクロヘキシル−アミン;
(4−クロロ−フェニル)−[2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−アミン;
[5−ブロモ−2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−(4−クロロ−フェニル)−アミン;
[2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−p−トリル−アミン;
(4−クロロ−フェニル)−[2−(3,5−ジメチル−ピラゾール−1−イル)−5−メチル−ピリミジン−4−イル]−アミン;
[5−ブロモ−2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−シクロヘキシル−アミン;又は
[5−クロロ−2−(3,5−ジメチル−ピラゾール−1−イル)−ピリミジン−4−イル]−(4−クロロ−フェニル)−アミン;
又は薬剤として許容されるその塩である、請求項1に記載のピラゾリル−ピリミジン誘導体。 Benzyl- [2- (3,5-dimethyl-pyrazol-1-yl) -6-methyl-pyrimidin-4-yl] -amine;
Cyclopentyl- [2- (3,5-dimethyl-pyrazol-1-yl) -6-methyl-pyrimidin-4-yl] -amine;
[2- (3,5-dimethyl-pyrazol-1-yl) -6-methyl-pyrimidin-4-yl] -diethyl-amine;
[2- (3,5-dimethyl-pyrazol-1-yl) -6-methyl-pyrimidin-4-yl] -phenyl-amine;
[2- (3,5-dimethyl-pyrazol-1-yl) -6-methyl-pyrimidin-4-yl] -p-tolyl-amine;
(3,4-dichloro-phenyl)-[2- (3,5-dimethyl-pyrazol-1-yl) -6-methyl-pyrimidin-4-yl] -amine;
[2- (3,5-dimethyl-pyrazol-1-yl) -6-methyl-pyrimidin-4-yl] -naphthalen-2-yl-amine;
[2- (3,5-dimethyl-pyrazol-1-yl) -pyrimidin-4-yl]-(3-trifluoromethyl-phenyl) -amine;
Cyclohexyl- [2- (3,5-dimethyl-pyrazol-1-yl) -pyrimidin-4-yl] -amine;
[5-chloro-2- (3,5-dimethyl-pyrazol-1-yl) -pyrimidin-4-yl] -cyclohexyl-amine;
(4-chloro-phenyl)-[2- (3,5-dimethyl-pyrazol-1-yl) -pyrimidin-4-yl] -amine;
[5-bromo-2- (3,5-dimethyl-pyrazol-1-yl) -pyrimidin-4-yl]-(4-chloro-phenyl) -amine;
[2- (3,5-dimethyl-pyrazol-1-yl) -pyrimidin-4-yl] -p-tolyl-amine;
(4-chloro-phenyl)-[2- (3,5-dimethyl-pyrazol-1-yl) -5-methyl-pyrimidin-4-yl] -amine;
[5-bromo-2- (3,5-dimethyl-pyrazol-1-yl) -pyrimidin-4-yl] -cyclohexyl-amine; or [5-chloro-2- (3,5-dimethyl-pyrazole-1 -Yl) -pyrimidin-4-yl]-(4-chloro-phenyl) -amine;
Or a pyrazolyl-pyrimidine derivative according to claim 1, which is a pharmaceutically acceptable salt thereof.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA200500415 | 2005-03-22 | ||
US66615405P | 2005-03-29 | 2005-03-29 | |
PCT/EP2006/060857 WO2006100212A1 (en) | 2005-03-22 | 2006-03-20 | Pyrazolyl-pyrimidines as potassium channel modulating agents and their medical use |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008534472A JP2008534472A (en) | 2008-08-28 |
JP2008534472A5 true JP2008534472A5 (en) | 2009-05-07 |
Family
ID=36390135
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008502385A Abandoned JP2008534472A (en) | 2005-03-22 | 2006-03-20 | Pyrazolyl-pyrimidine and its medical use as potassium channel modulators |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1863796A1 (en) |
JP (1) | JP2008534472A (en) |
WO (1) | WO2006100212A1 (en) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HN2005000795A (en) * | 2004-10-15 | 2010-08-19 | Aventis Pharma Inc | PYRIMIDINS AS ANTAGONISTS OF PROSTAGLANDINA D2 RECEPTOR |
JP2009519995A (en) | 2005-12-20 | 2009-05-21 | ノイロサーチ アクティーゼルスカブ | 2-Pyridin-2-yl-quinazoline derivatives as potassium channel modulators for the treatment of respiratory diseases |
JP2010505794A (en) | 2006-10-03 | 2010-02-25 | ノイロサーチ アクティーゼルスカブ | Indazolyl derivatives useful as potassium channel modulators |
US20100130516A1 (en) | 2007-03-28 | 2010-05-27 | Neurosearch A/S | Purinyl derivatives and their use as potassium channel modulators |
JP2010522719A (en) | 2007-03-28 | 2010-07-08 | ノイロサーチ アクティーゼルスカブ | Purinyl derivatives and their use as potassium channel modulators |
US20100179203A1 (en) * | 2007-07-04 | 2010-07-15 | Antonio Nardi | Novel pyrazole derivatives useful as potassium channel modulators |
CN101965176B (en) | 2008-02-08 | 2012-06-20 | 株式会社资生堂 | Whitening agent and skin external preparation |
WO2010026087A1 (en) | 2008-09-02 | 2010-03-11 | Neurosearch A/S | Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators |
US20110237607A1 (en) | 2008-09-26 | 2011-09-29 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
WO2010034707A1 (en) * | 2008-09-26 | 2010-04-01 | Neurosearch A/S | Substituted purinyl-pyrazol derivatives and their use as potassium channel modulators |
US8765770B2 (en) | 2009-04-01 | 2014-07-01 | Ataxion, Inc. | Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators |
EP2438069A1 (en) | 2009-04-01 | 2012-04-11 | NeuroSearch A/S | Substituted [1,2,4]triazolo[1,5-a]pyrimidines and their use as potassium channel modulators |
US20120095025A1 (en) | 2009-04-01 | 2012-04-19 | Neurosearch A/S | SUBSTITUTED [1,2,4]TRIAZOLO[1,5-a]PYRIMIDINES AND THEIR USE AS POTASSIUM CHANNEL MODULATORS |
US8592582B2 (en) | 2010-01-18 | 2013-11-26 | Shiseido Company, Ltd. | Method for producing pyrimidinylpyrazole compounds |
WO2013104577A1 (en) | 2012-01-11 | 2013-07-18 | Acesion Pharma Aps | Benzimidazolyl-acetamide derivatives useful as potassium channel modulators |
AU2016220096B2 (en) | 2015-02-17 | 2020-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Phenothiazine analogues as mitochondrial therapeutic agents |
CA2976937C (en) * | 2015-02-17 | 2023-04-04 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
AU2017275657B2 (en) * | 2016-06-02 | 2021-08-19 | Novartis Ag | Potassium channel modulators |
WO2018039077A1 (en) * | 2016-08-25 | 2018-03-01 | Arizona Board Of Regents On Behalf Of Arizona State University | Therapeutic compounds |
US9975886B1 (en) * | 2017-01-23 | 2018-05-22 | Cadent Therapeutics, Inc. | Potassium channel modulators |
US20230159500A1 (en) * | 2021-09-30 | 2023-05-25 | Chapman University | Sk channel positive allosteric modulators |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54117029A (en) * | 1978-02-28 | 1979-09-11 | Hokko Chem Ind Co Ltd | Agricultural and horticultural microbicide |
JPS6059883B2 (en) * | 1978-05-08 | 1985-12-27 | 北興化学工業株式会社 | Fungicide for agriculture and horticulture |
US6458823B1 (en) * | 1998-06-08 | 2002-10-01 | Wyeth | Diaminopyrazoles |
CZ20032233A3 (en) * | 2001-02-20 | 2004-12-15 | Bristol-Myers Squibb Company | Derivative of 2,4-disubstituted pyrimidine-5-carboxamide functioning as KCNQ potassium channel modulator |
AU2003212634A1 (en) * | 2002-03-11 | 2003-09-22 | Zetiq Technologies Ltd. | Compounds useful in the treatment of cancer |
TW200418835A (en) * | 2003-01-24 | 2004-10-01 | Tanabe Seiyaku Co | A pyrazolopyrimidine compound and a process for preparing the same |
KR20060032190A (en) * | 2003-07-02 | 2006-04-14 | 버텍스 파마슈티칼스 인코포레이티드 | Pyrimidines useful as modulators of voltage-gated ion channels |
-
2006
- 2006-03-20 JP JP2008502385A patent/JP2008534472A/en not_active Abandoned
- 2006-03-20 WO PCT/EP2006/060857 patent/WO2006100212A1/en not_active Application Discontinuation
- 2006-03-20 EP EP06725151A patent/EP1863796A1/en not_active Withdrawn
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2008534472A5 (en) | ||
JP2009519995A5 (en) | ||
JP2010505794A5 (en) | ||
JP2008533087A5 (en) | ||
US10463675B2 (en) | Aminopyrimidinyl compounds | |
AU2010339423C1 (en) | Therapeutic compounds and related methods of use | |
US7622486B2 (en) | Pyridine compounds, process for their preparation and compositions containing them | |
US20180258056A1 (en) | Amino quinazolines as kinase inhibitors | |
MXPA04007191A (en) | Pyrimidine derivatives as rho-kinase inhibitors. | |
PE20050691A1 (en) | PROCESS TO PREPARE 2-AMINOTIAZOL-5-AROMATIC CARBOXAMIDES AS KINASE INHIBITORS | |
JP2008520665A5 (en) | ||
JP2009532375A5 (en) | ||
JP2010522718A5 (en) | ||
CA2900308A1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
JP2020506895A (en) | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and / or tryptophan dioxygenase | |
JP2010502674A5 (en) | ||
CN108137513A (en) | Pyrimidine derivatives | |
EP3174876B1 (en) | Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity | |
US10202401B2 (en) | Process for making tetracyclic heterocycle compounds | |
US9428492B2 (en) | Secondary alcohol substituted triazoles as PDE10 inhibitors | |
CN102458409A (en) | Therapeutic applications in the cardiovascular field of quinazolinedione derivatives | |
JP7465266B2 (en) | Tricyclic compounds for the treatment and prevention of bacterial infections | |
WO2021240424A1 (en) | Indazole and benzoisoxazole dihydroorotate dehydrogenase inhibitors | |
JP2010509249A5 (en) | ||
JP2010515688A5 (en) |